已发表论文

16 项负面症状评估中文版的验证

 

Authors Huang B, Wang Y, Miao Q, Yu X, Pu C, Shi C

Received 25 February 2020

Accepted for publication 8 April 2020

Published 4 May 2020 Volume 2020:16 Pages 1113—1120

DOI https://doi.org/10.2147/NDT.S251182

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Yuping Ning

Purpose: The Negative Symptom Assessment-16 (NSA-16) is an instrument with significant validity and utility for assessing negative symptoms associated with schizophrenia. This study aimed to validate the Chinese version of the NSA-16.
Patients and Methods: A total of 172 participants with schizophrenia were assessed with the NSA-16, Scale for Assessment of Negative Symptoms (SANS), Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS) and Rating Scale for Extrapyramidal Side Effects (RSESE). The factor structure of the NSA-16 was evaluated via exploratory and confirmatory factor analysis. Cronbach’s α and intraclass correlation coefficients were computed. Correlations were evaluated via Spearman correlation coefficient.
Results: The original five-factor model of the NSA-16 did not fit our sample. Exploratory factor analysis followed by confirmatory factor analysis suggested a three-factor structure, consisting of communication, emotion and motivation, with 15 items. The NSA with 15 items was termed as the NSA-15. The NSA-15 showed excellent convergent validity by high correlations with the SANS and PANSS total and negative factor scores and good divergent validity by independence from the PANSS positive factor, CDSS and RSESE. The NSA-15 showed good internal consistency, interrater reliability and test–retest reliability.
Conclusion: The NSA-15 is best characterized by a three-factor structure and is valid for assessing negative symptoms of schizophrenia in Chinese individuals.
Keywords: negative symptoms, schizophrenia, NSA, reliability, validity




Figure 1 Confirmatory factor analysis of the 15-item negative symptom assessment (n=86).